NCT05893043View on ClinicalTrials.gov

A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 24, 2023

Primary Completion Date

June 28, 2023

Study Completion Date

June 28, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

GSBR-1290

Participants will receive GSBR-1290 oral capsules.

OTHER

Placebo

Participants will receive matching placebo oral capsules.

Trial Locations (1)

92801

ACT, Anaheim

All Listed Sponsors
lead

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

INDUSTRY